The University of Chicago Header Logo

Connection

George Perry to Alzheimer Disease

Back to Details
This is a "connection" page, showing publications George Perry has written about Alzheimer Disease.
George Perry
Connection Strength
20.851
Alzheimer Disease
  1. Central role of brain regulatory T cells in the inflammatory cascade in Alzheimer's disease. Proc Natl Acad Sci U S A. 2024 Aug 06; 121(32):e2412255121.
    View in: PubMed
    Score: 0.596
  2. Oxidative Stress in Alzheimer's Disease: The Shortcomings of Antioxidant Therapies. J Alzheimers Dis. 2024; 101(s1):S155-S178.
    View in: PubMed
    Score: 0.573
  3. Analysis of Alzheimer's Disease-Related Mortality Rates Among the Elderly Populations Across the United States: An Analysis of Demographic and Regional Disparities from 1999 to 2020. Curr Alzheimer Res. 2024; 21(6):384-394.
    View in: PubMed
    Score: 0.573
  4. Alzheimer's Disease: Not Just for the Aged? J Alzheimers Dis. 2023; 91(3):923-924.
    View in: PubMed
    Score: 0.535
  5. Lessons from antiamyloid-ß immunotherapies in Alzheimer's disease. Handb Clin Neurol. 2023; 193:267-292.
    View in: PubMed
    Score: 0.535
  6. Playing Russian Roulette with Alzheimer's Disease Patients: Do the Cognitive Benefits of Lecanemab Outweigh the Risk of Edema, Stroke and Encephalitis? J Alzheimers Dis. 2023; 92(3):799-801.
    View in: PubMed
    Score: 0.535
  7. Neuropathologic Changes Provide Insights into Key Mechanisms of Alzheimer Disease and Related Dementia. Am J Pathol. 2022 10; 192(10):1340-1346.
    View in: PubMed
    Score: 0.519
  8. SWADESH: A Comprehensive Platform for Multimodal Data and Analytics for Advanced Research in Alzheimer's Disease and Other Brain Disorders. J Alzheimers Dis. 2022; 85(1):1-5.
    View in: PubMed
    Score: 0.499
  9. Status and future directions of clinical trials in Alzheimer's disease. Int Rev Neurobiol. 2020; 154:3-50.
    View in: PubMed
    Score: 0.451
  10. Preventive and Therapeutic Strategies in Alzheimer's Disease: Focus on Oxidative Stress, Redox Metals, and Ferroptosis. Antioxid Redox Signal. 2021 03 10; 34(8):591-610.
    View in: PubMed
    Score: 0.451
  11. Neuroprotective and Antioxidant Effect of Ginkgo biloba Extract Against AD and Other Neurological Disorders. Neurotherapeutics. 2019 07; 16(3):666-674.
    View in: PubMed
    Score: 0.419
  12. The amyloid cascade and Alzheimer's disease therapeutics: theory versus observation. Lab Invest. 2019 07; 99(7):958-970.
    View in: PubMed
    Score: 0.409
  13. Analysis of post-translational modifications in Alzheimer's disease by mass spectrometry. Biochim Biophys Acta Mol Basis Dis. 2019 08 01; 1865(8):2040-2047.
    View in: PubMed
    Score: 0.402
  14. Towards an Integrative Understanding of tRNA Aminoacylation-Diet-Host-Gut Microbiome Interactions in Neurodegeneration. Nutrients. 2018 Mar 26; 10(4).
    View in: PubMed
    Score: 0.384
  15. Iron·ic facts about dementia. J Neurol Neurosurg Psychiatry. 2018 05; 89(5):446-447.
    View in: PubMed
    Score: 0.379
  16. Expression Profiling of Cytokine, Cholinergic Markers, and Amyloid-ß Deposition in the APPSWE/PS1dE9 Mouse Model of Alzheimer's Disease Pathology. J Alzheimers Dis. 2018; 62(1):467-476.
    View in: PubMed
    Score: 0.378
  17. Thermodynamics of Amyloid-ß Fibril Elongation: Atomistic Details of the Transition State. ACS Chem Neurosci. 2018 04 18; 9(4):783-789.
    View in: PubMed
    Score: 0.378
  18. Advances in Alzheimer's Diagnosis and Therapy: The Implications of Nanotechnology. Trends Biotechnol. 2017 10; 35(10):937-953.
    View in: PubMed
    Score: 0.365
  19. Modulation of Parkinson's Disease Associated Protein Rescues Alzheimer's Disease Degeneration. J Alzheimers Dis. 2017; 55(1):73-75.
    View in: PubMed
    Score: 0.353
  20. Nucleic acid oxidative damage in Alzheimer's disease-explained by the hepcidin-ferroportin neuronal iron overload hypothesis? J Trace Elem Med Biol. 2016 Dec; 38:1-9.
    View in: PubMed
    Score: 0.339
  21. High-resolution analytical imaging and electron holography of magnetite particles in amyloid cores of Alzheimer's disease. Sci Rep. 2016 04 28; 6:24873.
    View in: PubMed
    Score: 0.337
  22. Overview of Alzheimer's Disease and Some Therapeutic Approaches Targeting Aß by Using Several Synthetic and Herbal Compounds. Oxid Med Cell Longev. 2016; 2016:7361613.
    View in: PubMed
    Score: 0.329
  23. Mexico City normal weight children exposed to high concentrations of ambient PM2.5 show high blood leptin and endothelin-1, vitamin D deficiency, and food reward hormone dysregulation versus low pollution controls. Relevance for obesity and Alzheimer disease. Environ Res. 2015 Jul; 140:579-92.
    View in: PubMed
    Score: 0.316
  24. Parallels between major depressive disorder and Alzheimer's disease: role of oxidative stress and genetic vulnerability. Cell Mol Neurobiol. 2014 Oct; 34(7):925-49.
    View in: PubMed
    Score: 0.296
  25. The complexities of the pathology-pathogenesis relationship in Alzheimer disease. Biochem Pharmacol. 2014 Apr 15; 88(4):671-6.
    View in: PubMed
    Score: 0.287
  26. Lester (Skip) Binder (1949-2013): in the beginning was tau. J Alzheimers Dis. 2014; 40 Suppl 1:S5.
    View in: PubMed
    Score: 0.287
  27. Mitochondrial DNA oxidative damage and repair in aging and Alzheimer's disease. Antioxid Redox Signal. 2013 Jun 20; 18(18):2444-57.
    View in: PubMed
    Score: 0.266
  28. Pathogenesis and disease-modifying therapy in Alzheimer's disease: the flat line of progress. Arch Med Res. 2012 Nov; 43(8):694-8.
    View in: PubMed
    Score: 0.263
  29. Mark A. Smith: neurocytochemistry innovator. J Neurochem. 2012 Mar; 120(6):1139-40.
    View in: PubMed
    Score: 0.250
  30. Hydroxynonenal-generated crosslinking fluorophore accumulation in Alzheimer disease reveals a dichotomy of protein turnover. Free Radic Biol Med. 2012 Feb 01; 52(3):699-704.
    View in: PubMed
    Score: 0.247
  31. Mark A. Smith: the scientist, the man. Int J Exp Pathol. 2011 Oct; 92(5):297-8.
    View in: PubMed
    Score: 0.245
  32. Antioxidant approaches for the treatment of Alzheimer's disease. Expert Rev Neurother. 2010 Jul; 10(7):1201-8.
    View in: PubMed
    Score: 0.225
  33. Molecular pathogenesis of Alzheimer's disease: reductionist versus expansionist approaches. Int J Mol Sci. 2009 Mar; 10(3):1386-1406.
    View in: PubMed
    Score: 0.206
  34. RNA oxidation in Alzheimer disease and related neurodegenerative disorders. Acta Neuropathol. 2009 Jul; 118(1):151-66.
    View in: PubMed
    Score: 0.205
  35. Antioxidant therapy in Alzheimer's disease: theory and practice. Mini Rev Med Chem. 2008 Nov; 8(13):1395-406.
    View in: PubMed
    Score: 0.200
  36. Is US residence a risk factor for Alzheimer's disease? J Alzheimers Dis. 2025 Sep; 107(2):496-498.
    View in: PubMed
    Score: 0.161
  37. Hyperphosphorylated Tau Induces Cortical Hypoexcitability in Transgenic Mouse Models: A Meta-Analysis. J Integr Neurosci. 2025 Aug 28; 24(8):39192.
    View in: PubMed
    Score: 0.161
  38. Identifying patients with mild cognitive impairment at high risk of transitioning to Alzheimer's disease using routinely collected data. J Alzheimers Dis. 2025 Nov; 108(1_suppl):S334-S343.
    View in: PubMed
    Score: 0.159
  39. Conventional and Emerging Drug Targeting Sites in Alzheimer's Disease and the Role of Translational Informatics in its Diagnosis and Management. Curr Neuropharmacol. 2025; 23(14):1894-1917.
    View in: PubMed
    Score: 0.154
  40. Exacerbated mitochondrial dynamic abnormalities without evident tau pathology in rapidly progressive Alzheimer's disease. J Alzheimers Dis. 2024 Dec; 102(4):1074-1083.
    View in: PubMed
    Score: 0.152
  41. The Amyloid Cascade Hypothesis: A Conclusion in Search of Support. Am J Pathol. 2025 Nov; 195(11):1988-1997.
    View in: PubMed
    Score: 0.152
  42. Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US. Alzheimers Dement. 2024 Dec; 20(12):8661-8672.
    View in: PubMed
    Score: 0.152
  43. Sensory Dysfunction, Microbial Infections, and Host Responses in Alzheimer's Disease. J Infect Dis. 2024 Sep 10; 230(Supplement_2):S150-S164.
    View in: PubMed
    Score: 0.150
  44. Microglial modulation as a therapeutic strategy in Alzheimer's disease: Focus on microglial preconditioning approaches. J Cell Mol Med. 2024 Aug; 28(15):e18554.
    View in: PubMed
    Score: 0.149
  45. Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit. Ageing Res Rev. 2024 Aug; 99:102348.
    View in: PubMed
    Score: 0.147
  46. Label-Free In Situ Chemical Characterization of Amyloid Plaques in Human Brain Tissues. ACS Chem Neurosci. 2024 04 03; 15(7):1469-1483.
    View in: PubMed
    Score: 0.145
  47. Prion disease and Alzheimer's disease: pathogenic overlap. Acta Neurobiol Exp (Wars). 2004; 64(1):11-7.
    View in: PubMed
    Score: 0.143
  48. Meta-Analysis in Transgenic Alzheimer's Disease Mouse Models Reveals Opposite Brain Network Effects of Amyloid-ß and Phosphorylated Tau Proteins. J Alzheimers Dis. 2024; 99(2):595-607.
    View in: PubMed
    Score: 0.143
  49. Fueling Alzheimer's Disease: Where Does Immunometabolism Stand? J Alzheimers Dis. 2024; 100(s1):S363-S385.
    View in: PubMed
    Score: 0.143
  50. Endocrine Dyscrasia in the Etiology and Therapy of Alzheimer's Disease. J Alzheimers Dis. 2024; 101(3):705-713.
    View in: PubMed
    Score: 0.143
  51. Revision of Alzheimer's diagnostic criteria or relocation of the Potemkin village. Ageing Res Rev. 2024 01; 93:102173.
    View in: PubMed
    Score: 0.143
  52. Evaluation of N- and O-Linked Indole Triazines for a Dual Effect on a-Synuclein and Tau Aggregation. ACS Chem Neurosci. 2023 11 01; 14(21):3913-3927.
    View in: PubMed
    Score: 0.141
  53. Oxidative damage in the olfactory system in Alzheimer's disease. Acta Neuropathol. 2003 Dec; 106(6):552-6.
    View in: PubMed
    Score: 0.140
  54. Passive Alzheimer's immunotherapy: A promising or uncertain option? Ageing Res Rev. 2023 09; 90:101996.
    View in: PubMed
    Score: 0.138
  55. Establishment of a consensus protocol to explore the brain pathobiome in patients with mild cognitive impairment and Alzheimer's disease: Research outline and call for collaboration. Alzheimers Dement. 2023 11; 19(11):5209-5231.
    View in: PubMed
    Score: 0.138
  56. Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation. Am J Pathol. 2003 May; 162(5):1623-7.
    View in: PubMed
    Score: 0.137
  57. Damaged mitochondria coincide with presynaptic vesicle loss and abnormalities in alzheimer's disease brain. Acta Neuropathol Commun. 2023 03 31; 11(1):54.
    View in: PubMed
    Score: 0.136
  58. Circulating long non-coding RNAs as novel diagnostic biomarkers for Alzheimer's disease (AD): A systematic review and meta-analysis. PLoS One. 2023; 18(3):e0281784.
    View in: PubMed
    Score: 0.136
  59. Adventiously-bound redox active iron and copper are at the center of oxidative damage in Alzheimer disease. Biometals. 2003 Mar; 16(1):77-81.
    View in: PubMed
    Score: 0.135
  60. The Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes. J Alzheimers Dis. 2023; 94(2):497-507.
    View in: PubMed
    Score: 0.134
  61. Association of COVID-19 with Risk and Progression of Alzheimer's Disease: Non-Overlapping Two-Sample Mendelian Randomization Analysis of 2.6 Million Subjects. J Alzheimers Dis. 2023; 96(4):1711-1720.
    View in: PubMed
    Score: 0.134
  62. Hypoxic Preconditioning Averts Sporadic Alzheimer's Disease-Like Phenotype in Rats: A Focus on Mitochondria. Antioxid Redox Signal. 2022 Oct; 37(10-12):739-757.
    View in: PubMed
    Score: 0.128
  63. Making the Case for Accelerated Withdrawal of Aducanumab. J Alzheimers Dis. 2022; 87(3):1003-1007.
    View in: PubMed
    Score: 0.125
  64. Gut-microbiota-microglia-brain interactions in Alzheimer's disease: knowledge-based, multi-dimensional characterization. Alzheimers Res Ther. 2021 10 20; 13(1):177.
    View in: PubMed
    Score: 0.123
  65. Immune modulations and immunotherapies for Alzheimer's disease: a comprehensive review. Rev Neurosci. 2022 06 27; 33(4):365-381.
    View in: PubMed
    Score: 0.122
  66. The Amyloid-ß Pathway in Alzheimer's Disease. Mol Psychiatry. 2021 10; 26(10):5481-5503.
    View in: PubMed
    Score: 0.122
  67. Omics sciences for systems biology in Alzheimer's disease: State-of-the-art of the evidence. Ageing Res Rev. 2021 08; 69:101346.
    View in: PubMed
    Score: 0.119
  68. Decreased salivary lactoferrin levels are specific to Alzheimer's disease. EBioMedicine. 2020 Jul; 57:102834.
    View in: PubMed
    Score: 0.112
  69. No Evidence of Increased Chronic Traumatic Encephalopathy Pathology or Neurodegenerative Proteinopathy in Former Military Service Members: A Preliminary Study. J Alzheimers Dis. 2019; 67(4):1277-1289.
    View in: PubMed
    Score: 0.101
  70. Lithium as a Treatment for Alzheimer's Disease: The Systems Pharmacology Perspective. J Alzheimers Dis. 2019; 69(3):615-629.
    View in: PubMed
    Score: 0.101
  71. Diminished O-GlcNAcylation in Alzheimer's disease is strongly correlated with mitochondrial anomalies. Biochim Biophys Acta Mol Basis Dis. 2019 08 01; 1865(8):2048-2059.
    View in: PubMed
    Score: 0.100
  72. Differences in structure and function between human and murine tau. Biochim Biophys Acta Mol Basis Dis. 2019 08 01; 1865(8):2024-2030.
    View in: PubMed
    Score: 0.099
  73. Nanoscale synchrotron X-ray speciation of iron and calcium compounds in amyloid plaque cores from Alzheimer's disease subjects. Nanoscale. 2018 Jul 05; 10(25):11782-11796.
    View in: PubMed
    Score: 0.098
  74. Phosphorylation of Tau protein correlates with changes in hippocampal theta oscillations and reduces hippocampal excitability in Alzheimer's model. J Biol Chem. 2018 06 01; 293(22):8462-8472.
    View in: PubMed
    Score: 0.096
  75. Precision pharmacology for Alzheimer's disease. Pharmacol Res. 2018 04; 130:331-365.
    View in: PubMed
    Score: 0.095
  76. Inhibition of mitochondrial fragmentation protects against Alzheimer's disease in rodent model. Hum Mol Genet. 2017 11 01; 26(21):4118-4131.
    View in: PubMed
    Score: 0.093
  77. Mitochondrial traffic jams in Alzheimer's disease - pinpointing the roadblocks. Biochim Biophys Acta. 2016 10; 1862(10):1909-17.
    View in: PubMed
    Score: 0.086
  78. Alzheimer disease research in the 21st century: past and current failures, new perspectives and funding priorities. Oncotarget. 2016 Jun 28; 7(26):38999-39016.
    View in: PubMed
    Score: 0.085
  79. Laser-Induced In-Source Decay Applied to the Determination of Amyloid-Beta in Alzheimer's Brains. ACS Chem Neurosci. 2016 Mar 16; 7(3):261-8.
    View in: PubMed
    Score: 0.082
  80. Microbes and Alzheimer's Disease. J Alzheimers Dis. 2016; 51(4):979-84.
    View in: PubMed
    Score: 0.082
  81. Cerebrovascular and mitochondrial abnormalities in Alzheimer's disease: a brief overview. J Neural Transm (Vienna). 2016 Feb; 123(2):107-11.
    View in: PubMed
    Score: 0.077
  82. A clinical study of lupron depot in the treatment of women with Alzheimer's disease: preservation of cognitive function in patients taking an acetylcholinesterase inhibitor and treated with high dose lupron over 48 weeks. J Alzheimers Dis. 2015; 44(2):549-60.
    View in: PubMed
    Score: 0.077
  83. From Neurodegeneration to Brain Health: An Integrated Approach. J Alzheimers Dis. 2015; 46(1):271-83.
    View in: PubMed
    Score: 0.077
  84. Oxidative stress and mitochondrial dysfunction in Alzheimer's disease. Biochim Biophys Acta. 2014 Aug; 1842(8):1240-7.
    View in: PubMed
    Score: 0.071
  85. Apolipoprotein E4 prevents growth of malaria at the intraerythrocyte stage: implications for differences in racial susceptibility to Alzheimer's disease. J Health Care Poor Underserved. 2013 Nov; 24(4 Suppl):70-8.
    View in: PubMed
    Score: 0.071
  86. Antimicrobial peptide ß-defensin-1 expression is upregulated in Alzheimer's brain. J Neuroinflammation. 2013 Oct 18; 10:127.
    View in: PubMed
    Score: 0.071
  87. Is exercise-in-a-bottle likely to proffer new insights into Alzheimer's disease? J Neurochem. 2013 Oct; 127(1):4-6.
    View in: PubMed
    Score: 0.070
  88. The structures of the E22? mutant-type amyloid-ß alloforms and the impact of E22? mutation on the structures of the wild-type amyloid-ß alloforms. ACS Chem Neurosci. 2013 Feb 20; 4(2):310-20.
    View in: PubMed
    Score: 0.067
  89. The role of iron as a mediator of oxidative stress in Alzheimer disease. Biofactors. 2012 Mar-Apr; 38(2):133-8.
    View in: PubMed
    Score: 0.063
  90. Mark A. Smith, 1965-2010: consummate student of pathogenesis. Int J Clin Exp Pathol. 2011; 4(7):731-2.
    View in: PubMed
    Score: 0.061
  91. A novel origin for granulovacuolar degeneration in aging and Alzheimer's disease: parallels to stress granules. Lab Invest. 2011 Dec; 91(12):1777-86.
    View in: PubMed
    Score: 0.061
  92. Widespread distribution of reticulon-3 in various neurodegenerative diseases. Neuropathology. 2010 Dec; 30(6):574-9.
    View in: PubMed
    Score: 0.058
  93. Causes versus effects: the increasing complexities of Alzheimer's disease pathogenesis. Expert Rev Neurother. 2010 May; 10(5):683-91.
    View in: PubMed
    Score: 0.056
  94. Indoleamine 2,3-dioxygenase and 3-hydroxykynurenine modifications are found in the neuropathology of Alzheimer's disease. Redox Rep. 2010; 15(4):161-8.
    View in: PubMed
    Score: 0.054
  95. Evidence for the progression through S-phase in the ectopic cell cycle re-entry of neurons in Alzheimer disease. Aging (Albany NY). 2009 Apr; 1(4):382-8.
    View in: PubMed
    Score: 0.052
  96. Reexamining Alzheimer's disease: evidence for a protective role for amyloid-beta protein precursor and amyloid-beta. J Alzheimers Dis. 2009; 18(2):447-52.
    View in: PubMed
    Score: 0.051
  97. Cell cycle re-entry mediated neurodegeneration and its treatment role in the pathogenesis of Alzheimer's disease. Neurochem Int. 2009 Feb; 54(2):84-8.
    View in: PubMed
    Score: 0.050
  98. Alzheimer disease pathology as a host response. J Neuropathol Exp Neurol. 2008 Jun; 67(6):523-31.
    View in: PubMed
    Score: 0.049
  99. Antigen-antibody dissociation in Alzheimer disease: a novel approach to diagnosis. J Neurochem. 2008 Aug; 106(3):1350-6.
    View in: PubMed
    Score: 0.048
  100. Current approaches in the treatment of Alzheimer's disease. Biomed Pharmacother. 2008 Apr-May; 62(4):199-207.
    View in: PubMed
    Score: 0.048
  101. The role of novel chitin-like polysaccharides in Alzheimer disease. Neurotox Res. 2007 Dec; 12(4):269-74.
    View in: PubMed
    Score: 0.047
  102. Iron: the Redox-active center of oxidative stress in Alzheimer disease. Neurochem Res. 2007 Oct; 32(10):1640-5.
    View in: PubMed
    Score: 0.045
  103. Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees? Expert Rev Neurother. 2007 May; 7(5):473-85.
    View in: PubMed
    Score: 0.045
  104. Amyloid-beta in Alzheimer disease: the null versus the alternate hypotheses. J Pharmacol Exp Ther. 2007 Jun; 321(3):823-9.
    View in: PubMed
    Score: 0.044
  105. Increased expression of p130 in Alzheimer disease. Neurochem Res. 2007 Apr-May; 32(4-5):639-44.
    View in: PubMed
    Score: 0.043
  106. Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol. 2006 Jul; 65(7):631-41.
    View in: PubMed
    Score: 0.043
  107. Neuropathology in Alzheimer's disease: awaking from a hundred-year-old dream. Sci Aging Knowledge Environ. 2006 May 03; 2006(8):pe10.
    View in: PubMed
    Score: 0.042
  108. Neuropathology of Alzheimer disease: pathognomonic but not pathogenic. Acta Neuropathol. 2006 Jun; 111(6):503-9.
    View in: PubMed
    Score: 0.042
  109. Antioxidant protection and neurodegenerative disease: the role of amyloid-beta and tau. Am J Alzheimers Dis Other Demen. 2006 Mar-Apr; 21(2):126-30.
    View in: PubMed
    Score: 0.042
  110. Chitin-like polysaccharides in Alzheimer's disease brains. Curr Alzheimer Res. 2005 Oct; 2(4):419-23.
    View in: PubMed
    Score: 0.040
  111. Amyloid-beta in Alzheimer's disease: the horse or the cart? Pathogenic or protective? Int J Exp Pathol. 2005 Jun; 86(3):133-8.
    View in: PubMed
    Score: 0.040
  112. Oxidative stress and neurodegeneration. Ann N Y Acad Sci. 2005 Jun; 1043:545-52.
    View in: PubMed
    Score: 0.040
  113. Contribution of redox-active iron and copper to oxidative damage in Alzheimer disease. Ageing Res Rev. 2004 Jul; 3(3):319-26.
    View in: PubMed
    Score: 0.037
  114. Cerebral amyloid angiopathy: major contributor or decorative response to Alzheimer's disease pathogenesis. Neurobiol Aging. 2004 May-Jun; 25(5):599-602; discussion 603-4.
    View in: PubMed
    Score: 0.037
  115. Elevated expression of a regulator of the G2/M phase of the cell cycle, neuronal CIP-1-associated regulator of cyclin B, in Alzheimer's disease. J Neurosci Res. 2004 Mar 01; 75(5):698-703.
    View in: PubMed
    Score: 0.036
  116. Role of mitochondrial dysfunction in Alzheimer's disease. J Neurosci Res. 2002 Nov 01; 70(3):357-60.
    View in: PubMed
    Score: 0.033
  117. Molecular Processing of Tau Protein in Progressive Supranuclear Palsy: Neuronal and Glial Degeneration. J Alzheimers Dis. 2021; 79(4):1517-1531.
    View in: PubMed
    Score: 0.029
  118. The sterol regulatory element-binding protein 2 is dysregulated by tau alterations in Alzheimer disease. Brain Pathol. 2019 07; 29(4):530-543.
    View in: PubMed
    Score: 0.025
  119. Transplantation of Human Chorion-Derived Cholinergic Progenitor Cells: a Novel Treatment for Neurological Disorders. Mol Neurobiol. 2019 Jan; 56(1):307-318.
    View in: PubMed
    Score: 0.024
  120. Mfn2 ablation causes an oxidative stress response and eventual neuronal death in the hippocampus and cortex. Mol Neurodegener. 2018 02 01; 13(1):5.
    View in: PubMed
    Score: 0.024
  121. Beta-amyloid 1-42 monomers, but not oligomers, produce PHF-like conformation of Tau protein. Aging Cell. 2016 10; 15(5):914-23.
    View in: PubMed
    Score: 0.021
  122. Amyloid-ß peptide structure in aqueous solution varies with fragment size. J Chem Phys. 2011 Nov 28; 135(20):205101.
    View in: PubMed
    Score: 0.015
  123. The cell cycle regulator phosphorylated retinoblastoma protein is associated with tau pathology in several tauopathies. J Neuropathol Exp Neurol. 2011 Jul; 70(7):578-87.
    View in: PubMed
    Score: 0.015
  124. Modeling cholesterol metabolism by gene expression profiling in the hippocampus. Mol Biosyst. 2011 Jun; 7(6):1891-901.
    View in: PubMed
    Score: 0.015
  125. Paraffin-embedded tissue (PET) blot method: application to Alzheimer disease. J Neurosci Methods. 2010 Jul 15; 190(2):244-7.
    View in: PubMed
    Score: 0.014
  126. Phosphorylated tau: toxic, protective, or none of the above. J Alzheimers Dis. 2008 Aug; 14(4):377-83.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.